- Trial phase
- Not stated
- Time to market
- Not stated
- Why 2/10
- No hard, dated catalyst is scheduled for XEN1720 in the next ~12 months. The drug is not mentioned in any public pipeline disclosure, SEC filing, or clinical trial registry, and appears to be a preclinical or early discovery-stage program with no publicly announced development timeline.
XEN1720 is not a publicly disclosed development candidate. Xenon's pipeline is focused on azetukalner (epilepsy NDA submitted, depression Phase 3 data due December 2026) and two pain candidates (XEN1701, XEN1120) advancing to Phase 2. Until Xenon formally discloses XEN1720 as a named program, there is no actionable catalyst to track for this molecule.
Price Chart
Executive Summary
XEN1720 is not a publicly identified development candidate from Xenon Pharmaceuticals (XENE). Extensive searches of web news, SEC filings, ClinicalTrials.gov, press releases, and SecBot's internal databases found zero mentions of XEN1720 as an active drug program. Xenon's disclosed pipeline consists of azetukalner (XEN1101, its lead Kv7 potassium channel opener for epilepsy and depression), XEN1701 and XEN1120 (NaV1.7 pain candidates advancing to Phase 2), and earlier programs XEN496 and XEN901. The "XEN1720" designation does not correspond to any named compound in the company's public disclosures. It may be an internal research code for a very early discovery-stage molecule, but no information exists to evaluate it as an investable catalyst.
How It Works
The mechanism of XEN1720 is not publicly disclosed. Xenon Pharmaceuticals specializes in ion channel modulation for neuroscience, and its known pipeline candidates target voltage-gated sodium channels (NaV) for epilepsy and pain indications. XEN1720 may be an early-stage ion channel modulator, but this is speculative.
Trial Status
No clinical trial records for XEN1720 were found in ClinicalTrials.gov, SecBot's biotech pipeline database, or any SEC filing or press release. The drug name does not appear in any public Xenon Pharmaceuticals pipeline disclosure.
The Two-Sided Case
Upcoming Catalysts
- Xenon expects topline Phase 3 X-NOVA2 data for azetukalner in major depressive disorder in December 2026.
- XEN1701 and XEN1120 are advancing to Phase 2 proof-of-concept studies in acute pain (no specific date announced).
- The FDA is reviewing Xenon's NDA for azetukalner in focal onset seizures (submitted September 2026); a PDUFA date has not been publicly set.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Xenon Pharmaceuticals Inc. 8-K XENE ·Originating report